# Vitamin K and muscle health: mechanisms and clinical perspectives in sarcopenia and beyond: narrative review

**Authors:** Xiaoyu Ran, Yuqi Jiang, Linxiu Mao, Xiuhua Chen, Dan Jing, Xun Tang, Jing Tan

PMC · DOI: 10.3389/fnut.2026.1726483 · Frontiers in Nutrition · 2026-02-26

## TL;DR

Vitamin K may support muscle health through various mechanisms, but clinical trials have not yet confirmed its effectiveness in preventing or treating muscle loss.

## Contribution

This review highlights new mechanisms and clinical perspectives of vitamin K in muscle health beyond its traditional role in blood coagulation.

## Key findings

- Vitamin K influences muscle through γ-carboxylation and non-carboxylation pathways.
- Higher vitamin K intake is linked to better muscle strength and performance in older adults.
- RCTs show mixed results, possibly due to differences in isoforms and study designs.

## Abstract

Vitamin K, a fat-soluble micronutrient traditionally recognized for its role in blood coagulation, has increasingly been implicated as a micronutrient with emerging roles in skeletal muscle health. Experimental and clinical evidence now suggests that vitamin K influences skeletal muscle through both γ-carboxylation–dependent pathways—mediated by osteocalcin, matrix Gla protein (MGP), and growth arrest–specific 6 (Gas6)—and through non-carboxylation mechanisms, including anti-inflammatory, antioxidant, mitochondrial-regulatory, and ferroptosis-suppressing effects. Observational studies associate higher vitamin K intake and status with greater muscle strength, higher muscle mass, and better physical performance among older adults. However, findings from randomized controlled trials (RCTs) remain inconclusive, possibly due to differences in vitamin K isoforms, dosage, intervention duration, and study populations. Beyond age-related sarcopenia, vitamin K may also play a potentially protective role in muscle dysfunction associated with chronic diseases, including dialysis-related cramps and metabolic disorders. This review synthesizes recent mechanistic insights and clinical evidence, highlighting vitamin K as a biologically plausible contributor that is supported primarily by observational and mechanistic evidence for the prevention and management of sarcopenia and other muscle-related disorders, though its role remains incompletely validated.

## Linked entities

- **Genes:** bglap2 (bone gamma-carboxyglutamate (gla) protein (osteocalcin) 2) [NCBI Gene 100493875], MGP (matrix Gla protein) [NCBI Gene 4256], GAS6 (growth arrest specific 6) [NCBI Gene 2621]
- **Chemicals:** vitamin K (PubChem CID 5280483)

## Full-text entities

- **Genes:** BGLAP (bone gamma-carboxyglutamate protein) [NCBI Gene 632] {aka BGP, OC, OCN}, GAS6 (growth arrest specific 6) [NCBI Gene 2621] {aka AXLLG, AXSF}, MGP (matrix Gla protein) [NCBI Gene 4256] {aka GIG36, MGLAP, NTI}
- **Diseases:** cramps (MESH:D009120), sarcopenia (MESH:D055948), inflammatory (MESH:D007249), muscle dysfunction (MESH:D009135), blood coagulation (MESH:D001778), metabolic disorders (MESH:D008659), chronic diseases (MESH:D002908)
- **Chemicals:** Vitamin K (MESH:D014812)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12979126/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12979126/full.md

## References

114 references — full list in the complete paper: https://tomesphere.com/paper/PMC12979126/full.md

---
Source: https://tomesphere.com/paper/PMC12979126